Date published: 2025-12-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

MEK kinase-4 Inhibitors

MEK kinase-4 inhibitors belong to a specific chemical class of compounds that are designed to target and modulate the activity of the MEK kinase-4 enzyme. MEK kinase-4, also known as MAP2K4, is a crucial component of the mitogen-activated protein kinase (MAPK) signaling pathway, which plays a fundamental role in regulating various cellular processes, including cell proliferation, differentiation, and survival. The inhibitors work by specifically binding to the active site of the MEK kinase-4 enzyme, preventing its normal function and subsequent downstream signaling events. This blockade ultimately leads to the disruption of the MAPK signaling cascade, which can have far-reaching consequences on various cellular activities.

The specific structural features of MEK kinase-4 inhibitors allow them to interact with the enzyme in a highly selective manner, effectively blocking its catalytic function without significantly interfering with other cellular processes or related kinases. By modulating the activity of this kinase, these inhibitors have the potential to influence cellular responses to extracellular signals and contribute to the regulation of cell growth and differentiation.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

Targets MEK and thereby inhibits the activation of MAPK/ERK. It affects downstream of MAP3K4.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

Specifically inhibits p38 MAPK. As p38 is downstream of MAP3K4, this inhibitor can indirectly influence its activity.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

A selective JNK inhibitor, affecting the JNK pathway that can be activated by MAP3K4.

Doramapimod

285983-48-4sc-300502
sc-300502A
sc-300502B
25 mg
50 mg
100 mg
$149.00
$281.00
$459.00
2
(1)

Targets both p38 MAPK and JNK, influencing pathways downstream of MAP3K4.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$115.00
$415.00
11
(1)

B-Raf inhibitor, although it primarily targets B-Raf mutations, the overall MAPK pathway can be indirectly influenced.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$112.00
$163.00
$928.00
19
(1)

Inhibits MEK1 and MEK2 and thus has an indirect effect on upstream regulators like MAP3K4.

Selumetinib

606143-52-6sc-364613
sc-364613A
sc-364613B
sc-364613C
sc-364613D
5 mg
10 mg
100 mg
500 mg
1 g
$28.00
$80.00
$412.00
$1860.00
$2962.00
5
(1)

Another MEK inhibitor, potentially affecting the upstream activity of MAP3K4.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

Targets Raf and other kinases, potentially influencing the MAPK pathway.

Tipifarnib

192185-72-1sc-364637
10 mg
$720.00
(0)

Farnesyltransferase inhibitor that can impact the MAPK pathway, thereby having potential indirect effects on MAP3K4.